-transparent.png){kind=logo}
Different combinations of tuberculostatic drugs containing pyrazinamide were prescribed to 144 patients with pulmonary tuberculosis. In 3 months of treatment, bacterial excretion was observed in 89.7% of newly diagnosed patients and in 59% of cases with chronic forms of pulmonary tuberculosis. Side effects due to pyrazinamide were registered in 16.8% of the patients. In 2-3 months of therapy there were no differences traced in the condition of the liver, lipoid peroxidation or antioxidative activity as well as in a number of immunologic indices both in subjects receiving different combinations of antituberculous drugs, containing pyrazinamide, and in the control group of patients untreated with the drug.
M M Savula, and
M I Smolenko, and
M D Romaniuk, and
Iu I Slivka
November 1957,
Lotta contro la tubercolosi,
M M Savula, and
M I Smolenko, and
M D Romaniuk, and
Iu I Slivka
June 1965,
Tubercle,
M M Savula, and
M I Smolenko, and
M D Romaniuk, and
Iu I Slivka
January 1987,
Chemotherapy,
M M Savula, and
M I Smolenko, and
M D Romaniuk, and
Iu I Slivka
February 1957,
Minerva medica,
M M Savula, and
M I Smolenko, and
M D Romaniuk, and
Iu I Slivka
February 1957,
Minerva medica,
M M Savula, and
M I Smolenko, and
M D Romaniuk, and
Iu I Slivka
February 1957,
Minerva medica,
M M Savula, and
M I Smolenko, and
M D Romaniuk, and
Iu I Slivka
April 2019,
Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia,
M M Savula, and
M I Smolenko, and
M D Romaniuk, and
Iu I Slivka
April 1957,
La Riforma medica,
M M Savula, and
M I Smolenko, and
M D Romaniuk, and
Iu I Slivka
February 1957,
Minerva medica,
M M Savula, and
M I Smolenko, and
M D Romaniuk, and
Iu I Slivka
January 1956,
Il Friuli medico,
